SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Beat The Street With SI Traders

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: marcos who wrote (1507)7/27/2009 3:06:36 PM
From: Condor  Read Replies (1) of 233847
 
GAP.v
+++++++++++++++++++++++++++++++++++++++++++
News Story
PharmaGap cancer treatment results on tap
By Elizabeth Howell, Ottawa Business Journal Staff
Fri, Jul 17, 2009 8:00 AM EST

A day after announcing a $114,720 infusion of fundraised finances to fuel its cancer drug candidate, Ottawa-based PharmaGap Inc. (TSX-V:GAP) further stated it will release its first test results at some point next month.

The pharmaceutical company is putting PhG-alpha-1 through its paces at the Ottawa Hospital Research Institute and the U.S. National Cancer Research Institute (NCI).

The Ottawa Hospital's results on ovarian cancer cell treatment will be released during the first week of August, with the institute also planning to ramp up its test program to a second phase examining PhG-alpha-1's effectiveness in slowing ovarian cancer cell invasion and mobility.

Later that month, the NCI will release its analysis on the drug's ability to treat a variety of cancers ranging from breast, to kidney, to leukemia.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext